RhumbLine Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $645K | Buy |
+100,576
| New | +$645K | ﹤0.01% | 2508 |
|
|
2024
Q3 | – | Sell |
-28,779
| Closed | -$54.7K | – | 4199 |
|
|
2024
Q2 | $54.7K | Sell |
28,779
-40,624
| -59% | -$77.2K | ﹤0.01% | 3658 |
|
|
2024
Q1 | $197K | Buy |
69,403
+1,120
| +2% | +$3.18K | ﹤0.01% | 3188 |
|
|
2023
Q4 | $1.01M | Sell |
68,283
-677
| -1% | -$9.97K | ﹤0.01% | 2249 |
|
|
2023
Q3 | $1.26M | Buy |
68,960
+865
| +1% | +$15.8K | ﹤0.01% | 2082 |
|
|
2023
Q2 | $1.47M | Sell |
68,095
-7,867
| -10% | -$170K | ﹤0.01% | 2084 |
|
|
2023
Q1 | $2.23M | Buy |
75,962
+4,398
| +6% | +$129K | ﹤0.01% | 1750 |
|
|
2022
Q4 | $2.64M | Buy |
71,564
+25,771
| +56% | +$952K | ﹤0.01% | 1635 |
|
|
2022
Q3 | $1.29M | Buy |
45,793
+29,619
| +183% | +$834K | ﹤0.01% | 2007 |
|
|
2022
Q2 | $312K | Buy |
+16,174
| New | +$312K | ﹤0.01% | 2732 |
|